[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350263-105":59,"doc-detail-350263-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","endocrine-therapy-reprogramming-of-breast-cancer-facilitates-metastatic-escape-via-upregulation-of-p-rex1rac1-signaling","Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling","","Endocrine therapy drives initial control of ER+ breast cancer, yet ~30% of patients experience relapse years later with slowly proliferating, treatment-refractory disease. Slow-growing resistant cell models show that endocrine therapy reprograms these cells and upregulates Rac1 signalling through increased P-Rex1. Single-cell RNA sequencing links this switch to altered cell states, while clinical cohorts demonstrate higher P-Rex1 in ER+ tumors, including late recurrent cases. Intravital imaging confirms active Rac1 signalling after endocrine therapy, and Rac1-pathway inhibition impairs survival and motility, reducing tumor burden alone or combined with tamoxifen in xenograft models.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/endocrine-therapy-reprogramming-of-breast-cancer-facilitates-metastatic-escape-via-upregulation-of-p-rex1rac1-signaling/350263/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/endocrine-therapy-reprogramming-of-breast-cancer-facilitates-metastatic-escape-via-upregulation-of-p-rex1rac1-signaling/350263.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is late endocrine-therapy relapse in ER+ breast cancer considered a difficult clinical problem?","Question",{"text":113,"@type":114},"Relapses occur years after initial treatment, involve slowly proliferating disease, and often lack clear prognostic gene signatures or effective targeted options, contributing to substantial mortality.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does single-cell RNA sequencing reveal about cells treated with endocrine therapy?",{"text":118,"@type":114},"Single-cell RNA sequencing shows that endocrine therapy reprograms resistant cells with a notable upregulation of Rac1 signalling, specifically through increased P-Rex1.",{"name":120,"@type":111,"acceptedAnswer":121},"How was the Rac1 pathway validated as active and therapeutically targetable?",{"text":122,"@type":114},"P-Rex1 is high in ER+ clinical cohorts, intravital imaging demonstrates Rac1 signalling activity after endocrine therapy, and Rac1-pathway inhibitors reduce survival and motility while lowering tumor burden, especially when combined with tamoxifen.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350263,1790146316,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Article [https://doi.org/10.1038/s41467-026-70683-x](https://doi.org/10.1038/s41467-026-70683-x)  \nEndocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling  \nReceived: 11 July 2023  \n\n| Accepted: 2 March 2026 |\n| --- |\n| |\n| Check for updates |\n\nKristine J. Fernandez1,17, Ghazal Sultani1,2,17, Max Nobis 3, Brian Gloss4,  \nLeila Eshraghi1,2, Amy E. McCart Reed 5, Sarah Alexandrou 1,2, Christine Lee1, Daniel L. Roden1,2, Emily I. Jones6, Maryam Hasha Simad1,2, Ewan K. A. Millar7,8, Nenad Bartonicek1, Samantha R. Oakes2,9,10, Fatima Valdes-Mora 2,11, Yolanda Colino-Sanguino11, Ellie T. Y. Mok 1,2, Hannah L. Williams 1,12, Jamie R. Kutasovic5, Margaret C. Cummings5,13, Janett Stoehr 1, Victoria Lee1, Kate Harvey 1, Sunny Wu 1,2, Sunil R. Lakhani 5, Peter T. Simpson 5, Thomas R. Cox 1,2, Lisa M. Ooms 6, Christina A. Mitchell 6, Rob Salomon 14, Alexander Swarbrick 1,2, David Gallego-Ortega 1,2,15, Elgene Lim 1,2,16, Paul Timpson 1,2 & C. Elizabeth Caldon 1,2   \nThe estrogen receptor (ER) drives growth in most breast cancers. Endocrine therapy reduces recurrence, however around 30% of cancers relapse. Many recurrences occur years later, with slowly proliferating, hard-to-treat disease. To study this, we generate slow-growing resistant cells that form small primary tumours but readily metastasise. Single-cell RNA sequencing (scRNAseq) reveals that endocrine therapy reprograms these cells, notably upregulating the Rac1 signalling component P-Rex1. We ﬁnd in clinical cohorts that P-Rex1 is high in ER+breast cancer, including in late recurrent disease. Intravital imaging demonstrates that Rac1 signalling is active in ER+ cells following endocrine therapy. Targeting the Rac1 pathway with small molecule inhibitors (NSC23766, R-ketorolac) reduces survival and motility in resistant cells, inhibits in vivo Rac1 activity, and reduces tumour burden when combined with tamoxifen in a drug-refractory patient derived xenograft model. This work identiﬁes the P-Rex1/Rac1 axis as a potential therapeutic target for late recurring ER+ breast cancer.  \nEndocrine therapy (e.g. tamoxifen, fulvestrant, aromatase inhibitors)is the backbone of adjuvant therapy for the ~75% of breast cancer patients who have ER+ breast cancers. After initial surgery and treatment, patients receive endocrine therapy for 5–10 years to inhibit the growth of residual ER+ cancer cells. However, up to 30% of these patients develop incurable endocrine therapy resistant recurrences1. Commercially available gene signature tests (e.g. Oncotype DX) predict early and highly proliferative recurrences2 and provide a therapeutic decision tool on the addition of adjuvant chemotherapy to  \nenhance treatment3. However, ~50% of recurrences occur after >5–10 years of endocrine therapy3,4, and lead to ~50% of recurrence-related death. Unlike early recurrences, late recurrences lack a clear prognostic gene signature, and do not include the proliferative biomarkers that are associated with early recurrence. Late recurring ER+ breast cancers are an area of unmet need due to high mortality, difﬁculties in predicting the likelihood of occurrence, and lack of speciﬁc treatment.  \nThe current dogma is that late ER+ breast cancer recurrences are due to the reactivation of dormant cancer cells5,6. Dormancy can  \nA full list of afﬁliations appears at the end of the paper. e-mail: [l.caldon@garvan.org.au](l.caldon@garvan.org.au)  \nmanifest as “cellular dormancy” where cells enter a state of prolonged cell cycle arrest, or “tumour mass dormancy” where the proliferation of slowly cycling cells is counteracted by cellular turnover, and metastases do not reach the threshold of detection. Signiﬁcant efforts have been made towards exploring mechanisms of cellular dormancy, but the slow proliferative rate of primary ER+ cancer cells puts weight to the argument that tumour mass dormancy is an alternative route to late recurrence. In particular, measure","cbCaipnJei91ygYx","https://ap.wps.com/l/cbCaipnJei91ygYx","pdf",7220270,23,"English","# Endocrine therapy and late recurrence background\n## Modeling slow-growing endocrine-resistant disease\n# Rac1/P-Rex1 axis activation after therapy\n## Clinical cohort validation\n## Intravital imaging of signalling activity\n# Therapeutic targeting of the Rac1 pathway\n## Small-molecule inhibition and in vivo effects\n# Metastatic growth rate and proliferation\n## Ki67 comparison of primary versus matched metastases\n# Development of slow-growing resistance models\n## Rationale for model design","[{\"question\":\"Why is late endocrine-therapy relapse in ER+ breast cancer considered a difficult clinical problem?\",\"answer\":\"Relapses occur years after initial treatment, involve slowly proliferating disease, and often lack clear prognostic gene signatures or effective targeted options, contributing to substantial mortality.\"},{\"question\":\"What does single-cell RNA sequencing reveal about cells treated with endocrine therapy?\",\"answer\":\"Single-cell RNA sequencing shows that endocrine therapy reprograms resistant cells with a notable upregulation of Rac1 signalling, specifically through increased P-Rex1.\"},{\"question\":\"How was the Rac1 pathway validated as active and therapeutically targetable?\",\"answer\":\"P-Rex1 is high in ER+ clinical cohorts, intravital imaging demonstrates Rac1 signalling activity after endocrine therapy, and Rac1-pathway inhibitors reduce survival and motility while lowering tumor burden, especially when combined with tamoxifen.\"}]","Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling | PDF",1790088154,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cf450970bd1d8ee9556f0baf515a325.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4cddb4988772b220f4931e13829fe57.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b356132f78ef895d23ce504c17825fd.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aec149cf34e317c60259b71a1032a185.webp",980,1301]